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Abstract
Objective: Glucocorticoid (GC) sensitivity is highly variable among individuals and has been
associated with susceptibility to develop (auto-)inflammatory disorders. The purpose of the
study was to assess GC sensitivity in Behc¸et’s disease (BD) by studying the distribution of four
GC receptor (GR) gene polymorphisms and by measuring in vitro cellular GC sensitivity.
Methods: Healthy controls and patients with BD in three independent cohorts were
genotyped for four functional GR gene polymorphisms. To gain insight into functional
differences in in vitro GC sensitivity, 19 patients with BD were studied using two bioassays
and a whole-cell dexamethasone-binding assay. Finally, mRNA expression levels of GR splice
variants (GR-a and GR-b) were measured.
Results: Healthy controls and BD patients in the three separate cohorts had similar
distributions of the four GR polymorphisms. The Bcll and 9b minor alleles frequency differed
significantly between Caucasians and Mideast and Turkish individuals.
At the functional level, a decreased in vitro cellular GC sensitivity was observed. GR number
in peripheral blood mononuclear cells was higher in BD compared with controls. The ratio of
GR-a/GR-b mRNA expression levels was significantly lower in BD.
Conclusions: Polymorphisms in the GR gene are not associated with susceptibility to BD.
However, in vitro cellular GC sensitivity is decreased in BD, possibly mediated by a relative
higher expression of the dominant negative GR-b splice variant. This decreased in vitro GC
sensitivity might play an as yet unidentified role in the pathophysiology of BD.
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Introduction
Behc¸et’s disease (BD) is an inflammatory disorder charac-
terized by recurrent episodes of orogenital ulcers, uveitis,
arthritis, and skin lesions. Less frequent symptoms include
gastrointestinal lesions and involvement of the central
and peripheral nervous system. The onset of disease is
typically in the third or fourth decade of life and equally
affects men and women.
BD is common along the ancient Silk Road, which
extends from Eastern Asia to the Mediterranean area. The
highest prevalence occurs in Turkey (80–420 cases per
100.000), followed by Middle and Far Eastern countries
(13.5–20 cases per 100.000). In contrast, the prevalence in
Western countries is much lower; w0.12–5.1 per 100.000
(1, 2, 3).
The etiology of BD is unknown. It is mainly
considered a multi-factorial disease and it is associated
with the presence of human leukocyte antigen variants, in
particular HLA-B51 (3). Variations in several other genes
like the tumor necrosis factor, interleukin 10 (IL10),
and the nucleotide-binding oligomerization domain
containing two (NOD2) genes are also associated with
BD (4, 5, 6). Immunohistochemically, BD is characterized
by the presence of vasculitis and infiltration of tissue by
neutrophils and mononuclear cells (7).
Interestingly, BD also displays some features distinc-
tive of autoimmune processes. First, cellular immunity
is disturbed in BD as exemplified by autoreactive T
cells-targeting heat shock protein 60 (8). For many
autoimmune disorders, autoreactive T cells are a primary
culprit in their pathogenesis. Second, several autoanti-
bodies have been described targeting numerous antigens,
including CTLA-4 (9) (enhancing T cell proliferation),
retinal S-antigen (10), and antikinectin (11), providing
evidence for a dysfunctional humoral immune response.
In general, BD might be regarded an immune-mediated
inflammatory disease.
Glucocorticoids (GC) play a key role in mediating a
balanced inflammatory response. GCs exert their effects via
interaction with the GC receptor (GR). After binding with its
ligand, the GR–GC complex migrates to the nucleus to
induce (‘transactivation’) or to suppress (‘transrepression’)
expression of target genes. The ultimate biological effects of
(endogenous) GC depend on the GC sensitivity of an
individual, which is influenced by both genetic and
acquired (disease-related) factors. Hence, decreased GC
sensitivity could lead to unrestricted immune activation
and facilitation of a chronic inflammatory process, a
hallmark of many autoimmune disorders.
Indeed, decreased GC sensitivity has been shown to be
involved in several autoimmune diseases. For instance,
carriers of polymorphisms of the GR gene associated with
reduced (i.e. 9b) or increased (i.e. Bcll and N363S) GC
sensitivity have increased, respectively, decreased suscep-
tibility to develop rheumatoid arthritis (RA). In addition,
carriers of the ER22/23EK allele of the GR gene, which is
associated with decreased GC sensitivity, had a more
severe disease course (12). At the functional level, van
Winsen et al. (13) showed that in patients with multiple
sclerosis, higher doses of dexamethasone were required to
suppress LPS-induced TNF-a production in peripheral
blood mononuclear cells (PBMC) when compared with
healthy controls. Also in active RA, PBMCs were less
sensitive to dexamethasone in vitro (14). Finally, an
increased expression of the GR splice variant GR-b, the
dominant negative inhibitor of the biologically active
GR-a, is associated with GC resistance in several inflam-
matory disorders (15, 16, 17, 18, 19, 20).
As decreased GC sensitivity may contribute to
immune-mediated inflammatory diseases, we hypothe-
sized that decreased GC sensitivity is involved in the
pathophysiology of BD. To test our hypothesis, we
genotyped three independent cohorts of patients with
BD for the prevalence of four functional GR polymorph-
isms. Furthermore, in vitro GC sensitivity was assessed by
measurement of GR-binding capacity (GR number and
affinity) and by two bioassays (21). In these bioassays,
dexamethasone-regulated expression of IL2 and GC-
induced leucine zipper (GILZ) in PBMC is measured.
Transrepressive effects of GC, traditionally considered
to be the predominant mechanism regulating anti-
inflammatory actions of GC, are represented by the IL2
assay. The GILZ assay embodies all transactivated genes,
mediating both anti-inflammatory effects of GC as well as
(metabolic) side effects (22, 23). Using these bioassays, a
spectrum of GC sensitivity could be demonstrated in
healthy individuals (21). Finally, we measured mRNA
expression levels of GR-a and GR-b.
Patients and methods
Patients
To study the prevalence and distribution of the GR
polymorphisms, three cohorts with a total of 290
unrelated BD patients were included in the study (56
patients from the Erasmus MC, Rotterdam; 109 patients
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from The Jordan Hospital, Amman, Jordan and St John’s
Ophthalmic Hospital, Jerusalem, Israel; 39 patients from
St Thomas’ Hospital, London, UK, and 86 patients from
the University of Cukurova, Adana, Turkey. Of those, 55
were Caucasians, 125 of Middle Eastern (ME) origin or
Arab descent, and 110 patients were of Turkish descent.
The control population consisted of 150 Turkish and
75 ME individuals. Caucasian controls (nZ5295–5413,
depending on polymorphism) were participants in the
Rotterdam Study, a population-based prospective cohort
study on determinants of disease and disability in persons,
aged 55 years and older, living in Rotterdam, The
Netherlands.
To study functional differences in in vitro GC
sensitivity in patients with BD, 19 consecutive BD patients
from our outpatient clinic were included in the study.
Experienced clinical immunologists ( J A M vL and P M vH)
examined all patients and assessed disease activity using
the validated BD current activity form (BDCAF) (24). As a
control group, we studied 20 healthy Caucasian laboratory
employees. None of the patients or controls used GCs in
the last 3 months. All patients described in this study
fulfilled the International Study Group criteria for the
diagnosis of BD (25).
GR polymorphisms
All patients and controls were genotyped for four
functional polymorphisms of the GR gene (ER22/23EK,
rs6189 and rs6190; N363S, rs6195; Bcll, rs41423247 and
9b, rs6198) (26). DNA was extracted from peripheral
venous blood samples using standard techniques. DNA
(1–2 ng) was dispensed in 384-well plates. PCR amplifi-
cation (initial denaturation at 95 8C for 15 min, 40 cycles
with denaturation of 15 s at 95 8C, and annealing and
extension at 60 8C) and genotyping was performed using
the Taqman allelic discrimination assay. Results were
analyzed by Taqman Prism 7900HT using the sequence
detection system 2.2 software (Applied Biosystems,
Nieuwerkerk a/d IJssel, The Netherlands).
Assessment of in vitro GC sensitivity
Functional in vitro assays " Recently, two bioassays to
determine GC sensitivity were developed in our laboratory
(21). In short, peripheral blood was drawn in all patients
using Cell Preparation Tubes with sodium heparin
(Becton Dickinson, Breda, The Netherlands) allowing
isolation of PBMC. Cells were resuspended in RPMI 1640
medium containing L-glutamine supplemented with peni-
cillin (100 U/ml), streptomycin (100 mg/ml), and 10% fetal
bovine serum, and precultured overnight in a 48-well plate
(Costar, Amsterdam, The Netherlands) at a density of
4.0!106/ml. Trypan blue staining revealed the viability of
isolated cells to beO95%. The next day, cells were incubated
with increasing doses of dexamethasone (range 0–333 nM)
and stimulated with phytohaemagglutinin 10 mg/ml
(Sigma–Aldrich). After 4 h in the incubator, total RNA of
the cells was collected (total RNA isolation Kit, Roche).
cDNA was synthesized using 100 ng RNA and Taqman
Reverse Transcription Reagent (N808-0234, Applied
Biosystems). For quantitative real-time PCR analysis, the
Taqman Technology was applied according to the manufac-
turer’s instructions. GC-specific transactivation of the GILZ
mRNA and transrepression of the IL2 mRNA were measured.
Half maximal effective concentration (EC50) was used as a
readout for in vitro GC sensitivity. The EC50 values of GILZ
and IL2 in PBMC were comparable when different
compositions of lymphocytes and monocytes were tested
(data not shown). In addition, we measured the affinity and
number of GR using a whole cell dexamethasone-binding
assay, as described previously (27).
Gene expression levels of GR isoforms " After
isolation of PBMC as described above, 1!106 PMBCs
Table 2 Patient characteristics. Values are presented as
number (%), unless otherwise stated.
Healthy
controls
(nZ20)
Behc¸et’s
disease
(nZ19)
Female gender 10 (50) 12 (63.2)
Age (years), mean (S.D.) 31.8 (9.7) 43.3 (10.6)
Caucasian ethnicity 20 (100) 5 (26.3)
BDCAF, median (range) – 12 (0–30)
Phenotype of disease (ever)
Oral ulcers – 19 (100)
Genital ulcers – 17 (89.5)
Arthralgia/arthritis – 15 (78.9)
Gastrointestinal involvement – 15 (78.9)
Uveitis/vasculitis retinae – 11 (57.9)
Positive pathergy test – 4 (21.1)a
Erythema nodosum – 11 (57.9)
Pustulopapular skin lesions – 15 (78.9)
BDCAF, Behc¸et’s disease current activity form.
aThree patients never underwent a pathergy test.
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(in duplicate) were lysed and total RNA was extracted
immediately (Total RNA isolation Kit, Roche). cDNA was
synthesized using 200 ng RNA and Taqman Reverse
Transcription Reagent (N808-0234, Applied Biosystems)
in a total volume of 50 ml. Gene expression levels of
GR-a and GR-b were measured using premanufactured
assays (Applied Biosystems, Hs00230818_m1 and
Hs00354508_m1 respectively). All results were corrected
for the housekeeping gene hypoxanthine phosphoribosyl-
transferase 1 (HPRT1).
Statistical analysis
To analyze possible associations between GR genotypes
and risk of having BD, we calculated odds ratios and 95%
confidence intervals for hetero- and homozygous individ-
uals separately (wildtype allele as reference). Given the low
number homozygous carriers of the N363S and ER22/23EK
minor allele, hetero- and homozygous carriers were
analyzed together. Pearson c2-tests were performed to
test for differences in distribution of the polymorphisms
between the various ethnic groups. Differences in continu-
ous variables between the cohorts were tested using
Mann–Whitney U tests and ANOVA. IL2-EC50 was
square-root transformed and number of receptors and KD
were both natural logarithm transformed to normalize the
data. All statistical analysis was performed using SPSS for
Windows, release 17.0 (SPSS, Chicago, IL, USA) and we
considered differences statistically significant if P values
were !0.05 (two-sided).
Ethical approval
This study was approved by the medical ethics committee
of the Erasmus Medical Center and all subjects signed
informed consent.
Results
GR polymorphisms
Healthy controls and BD patients in the three separate
cohorts had similar distributions of the four GR poly-
morphisms (Table 1). Prevalence of the Bcll minor allele
was significantly higher in Caucasians compared with
both Turkish and ME persons (37.1% in Caucasians vs 21.5
and 21.0% in Turkish and ME persons, respectively,
P!0.001). In contrast, the 9b minor allele was less
prevalent in Caucasians compared with the Turkish and
ME persons (17.2% in Caucasians vs 28.5 and 29.6% in
Turkish and ME persons, respectively, P!0.001).
In vitro GC sensitivity
We included 19 BD patients from our outpatient clinic.
These patients used a wide spectrum of anti-inflammatory
agents, including NSAIDs (nZ7, 36.8%), colchicine (nZ5,
Figure 1
Cellular GC sensitivity in Behc¸et’s disease and healthy controls. EC50
(nM DEX) values of interleukin 2 (A) and glucocorticoid (GC)-induced
leucine zipper (B) of dexamethasone-treated PBMC. Number of GR per cell
and KD of the GC receptor using a whole cell-binding assay are depicted in
C and D respectively. Triangles (closed triangle) are Caucasian subjects;
squares (closed square) represent Turkish–ME subjects. Please note the
square-root transformed Y-axis in figure (A) and the logarithmically
transformed Y-axis in figure (C) and (D).
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26.3%), hydroxychloroquine (nZ4, 21.1%), TNF-a block-
ers (nZ2, 10.5%), and pentoxifylline (nZ3, 15.8%).
Thalidomide, methotrexate, interferon-alfa, and octreo-
tide were each used by one patient. Further baseline
characteristics and clinical features (present at any time in
the disease course) are summarized in Table 2. None of the
patients had involvement of the central nervous system.
Patients with BD had higher mean EC50 values in both
the IL2 assay and GILZ assay compared with healthy
controls (mean IL2 EC50 (95% CI): 10.80 (7.91–14.15) nM
in BD vs 3.48 (2.16–5.10) nM in HC, P!0.001; mean GILZ
EC50 (95% CI): 12.16 (10.91–13.42) nM in BD vs 8.13
(6.69–9.58 nM) in HC, P!0.001) indicating decreased
in vitro GC sensitivity in BD (Fig. 1). The maximum
induction of GILZ and repression of IL2 did not differ
significantly (data not shown). The GR number in PBMC
(mean, 95% CI) was higher in BD (10380, 8593–12539
GR/cell) compared with controls (6652, 5719–7738
GR/cell, PZ0.001), whereas the mean KD (95% CI) of
the receptor did not differ between patients (8.34,
6.62–10.50 nM) and controls (8.46, 7.37–9.71 nM). Impor-
tantly, the EC50 values of GILZ and IL2 and the number of
GR did not differ significantly between Caucasian and
Turkish and ME patients (Fig. 1). Patients and healthy
controls had comparable percentages of monocytes
(meanGS.D.: 18.9G5.5 in BD vs 20.9G5.0 in healthy
controls). Ligand affinity of monocytes and lymphocytes
did not differ significantly. The number of GRs per cell was
about three fold higher in monocytes as compared with
lymphocytes (data not shown).
No correlations were found between the BDCAF-score
and parameters of in vitro GC sensitivity. Men and women
had equal mean levels of IL2-EC50 and GILZ-EC50. Like-
wise, there were no gender differences at the level of the
number of GR or the affinity of the GR.
In 12 BD patients and healthy controls, mRNA
expression levels of GR-a and GR-b were measured. BD
patients showed a trend toward lower mRNA expression
levels of GR-a whereas mRNA expression levels of GR-b
tended to be higher. Combined, the GR-a/GR-b ratio was
significantly lower in patients (PZ0.014; Fig. 2).
Discussion
The results of our study suggest that decreased GC
sensitivity might play a role in the pathophysiology of
BD. More specifically, both transactivating and transre-
pressing pathways of GC action seem to be affected in BD,
together with an altered expression of the GR in PBMC. At
the transcriptional level, a lower GR-a/GR-b ratio was
observed in BD.
We examined the prevalence of four functional GR
polymorphisms in three independent cohorts. None of
the GR polymorphisms was associated with susceptibility
to BD, consistent with two recent genome-wide associ-
ation studies from Turkey and Japan (5, 28). However, we
found significant differences in the prevalence of GR
Figure 2
mRNA expression levels of the glucocorticoid receptor isoforms in PBMC of
patients with Behc¸et’s disease and healthy controls. GR-a is the biologically
active isoform (A), GR-b acts as a dominant negative isoform (B). The ratio
of GR-a/GR-b is shown in C. Triangles (closed triangle) are Caucasian
subjects; squares (closed square) represent Turkish–ME subjects.
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polymorphisms between the Caucasian and Turkish and
ME cohort, which have not been reported before. The BclI
minor allele is associated with increased GC sensitivity
(26) and is present at a lower frequency in the Turkish–ME
cohort. The Bcll minor allele is also less prevalent in other
areas with relatively high prevalence of BD (e.g. China,
Korea), as compared with allele frequencies observed in
Caucasian populations (29, 30). On the other hand, the
9b minor allele, which is associated with decreased GC
sensitivity (26), showed a lower prevalence in the
Caucasian population. The clinical relevance of these
observations is yet unclear, but they do not directly
support the concept of a ‘GC-resistant’ genetic profile
contributing to the development of BD as a comparable
prevalence of the Bcll and 9b minor alleles was found in
the Turkish and ME patients and healthy controls. Future
studies should examine whether the different prevalence
pattern of GR polymorphisms in the Turkish–ME popu-
lation is associated with other immune-mediated
disorders.
To further explore the role of GC sensitivity in BD, we
assessed transactivating and transrepressing capacity of
GC in vitro by measuring the EC50 values of two
representative GC-mediated genes, GILZ (TSC22D3) and
IL2. We measured higher EC50 values of both genes in BD,
indicating decreased in vitro GC sensitivity compared with
healthy controls. In contrast, we found higher numbers of
GR per cell, which might reflect a compensatory upregula-
tion of the GR. Importantly, most patients in our study
had relatively low BDCAF scores, suggesting that the
higher EC50 values are not solely influenced by higher
levels of pro-inflammatory cytokines, a well-known
mechanism of acquired GC resistance (31). Diminished
(counterbalancing) cellular effects of GC on the immune
system could allow for the development of chronic (auto)-
inflammatory processes as in BD. A point of future
attention is that in this relatively small group of patients
there was considerable variation with respect to the
use/not use of disease-modifying drugs. In this setting, it
was not possible to analyze the possible effects of these
drugs on the outcome of the assays.
In clinical practice, GCs are widely used in BD.
However, the only randomized clinical trial studying the
effects of GC in BD showed a lack of efficacy of GC
treatment. In this study, 3-weekly depots of 40 mg
methylprednisolone acetate during 27 weeks in patients
with active BD demonstrated no benefit over placebo-
treated patients with respect to orogenital ulcers, follicu-
litis, and arthritis, although lesions with erythema
nodosum did improve following GC treatment (32).
Interestingly, in asthma and RA approximately one-third
of patients are also GC resistant (33, 34). In addition, a case
series reported by Tanaka et al. (35) showed that patients
who had ocular manifestations of BD with low in vitro GC
sensitivity had a worse clinical course as defined by more
frequent relapses of ocular inflammation and higher intra-
ocular pressure. Therefore, the observed decreased in vitro
GC sensitivity in BD may not only contribute to an
increased understanding of the (etio) pathophysiology of
the disease but could also have direct clinical implications.
Obviously, it would be of great interest to study whether
assessment of in vitro GC sensitivity, as measured by the
IL2, GILZ, and whole cell dexamethasone-binding assays,
correlates with in vivo response to GC therapy in BD.
Insights in the patients response to exogenously adminis-
tered GC before the start of therapy could then be used to
facilitate more individualized GC therapy.
In order to examine possible mechanisms underlying
this decreased GC sensitivity in BD, we determined mRNA
expression levels of the a and b splice variant of the GR.
GR-b is thought to act as a dominant negative inhibitor of
the biologically active GR-a by means of competition for
co-factors, formation of inactive heterodimers with GR-a,
and possibly competition for GRE in vitro (15, 16, 19). High
expression of GR-b in vivo has been associated with
GC-resistant states in inflammatory bowel disease, asthma,
and RA (17, 18, 20, 36, 37). In our cohort, the ratio of
GR-a/GR-b was significantly lower in patients with BD and
could therefore partially explain the decreased cellular GC
sensitivity in BD, although the clinical relevance of the
very low expression levels of GR-b are still the subject of
debate. Other mechanisms possibly underlying the
decreased cellular GC sensitivity in BD may include
disturbed nuclear trafficking of the GR via phosphomodu-
lation by kinases and phosphatases, interference with the
transcriptional machinery by histone acetyltransferases
modulating protein acetylation or transcriptional blocking
by altered expression of micro-RNAs.
It must be kept in mind that our data represent
relatively small groups, with mixed ethnic background.
In this perspective, it is important to note that the
Caucasian and Turkish–ME patients with BD were equally
distributed with respect to the bioassays, GR assay, and the
gene expression levels. Therefore, we assumed that ethnic
background is not a major factor determining outcomes of
the bioassay, GR assay or gene expression levels, and
analyzed Caucasian and Turkish–ME patients together.
Also, mRNA levels of GR-a and GR-b do not necessarily
represent protein expression levels in our patients. Finally,
the interpretation of cross-sectional data is limited with
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Research R A M Quax et al. Glucocorticoid sensitivity in
Behc¸et’s disease
7–9 1 :109
http://www.endocrineconnections.org
DOI: 10.1530/EC-12-0056
 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
respect to dynamic processes as the pathogenesis of BD.
Therefore, longitudinal studies evaluating GC sensitivity
at various stages of BD, including recent-onset disease, and
different levels of disease activity will provide more insight
into the importance of GC sensitivity and the develop-
ment of BD.
In conclusion, polymorphisms of the GR gene are not
associated with susceptibility to BD. However, our in vitro
data indicate decreased cellular GC sensitivity in BD. This
altered GC sensitivity could play an as yet unidentified
role in the etiopathophysiology of BD. A decreased
GR-a/GR-b ratio may in part explain this decreased GC
sensitivity.
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